Format

Send to

Choose Destination
J Oncol Res Ther. 2017;3(5). pii: 139. Epub 2017 Dec 20.

Anti-Androgen Abiraterone Acetate Improves the Therapeutic Efficacy of Statins on Castration-Resistant Prostate Cancer Cells.

Author information

1
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE, USA.
2
BioBank/Tissue Bank, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, China.
3
Section of Urological Surgery, School of Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
4
Department of Pharmacology, Creighton University School of Medicine, Omaha, NE, USA.
5
Human Genetic Laboratory, Munroe-Meyer Institute, University of Nebraska Medical Center, Omaha, NE, USA.
6
Eppley Institute for Cancer Research, University of Nebraska, Medical Center, Omaha, NE, USA.
7
College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, China.

Abstract

The treatment of castration-resistant (CR) prostate cancer (PCa) is limited. A sub-population of CR PCa tumors can synthesize androgens for intracrine androgen receptor (AR) activation, thus targeting androgen biosynthesis could be an effective therapeutic option for these patients. We determined that androgen biosynthesis inhibitors simvastatin, atorvastatin, and ketoconazole directly inhibit growth, migration, and colony formation of LNCaP C-81 cells, which exhibit de novo androgen biosynthesis, with simvastatin being the most effective. Importantly, in combination treatments, statins specifically enhanced growth suppression with added effects by anti-androgen abiraterone acetate on the CR PCa cells. Thus, statins can be used in conjunction with abiraterone acetate to enhance anti-androgen therapy for CR PCa.

KEYWORDS:

Anti-Androgens; Castration-Resistant Prostate Cancer; Combination Treatments; Prostate Cancer; Statins

PMID:
31328181
PMCID:
PMC6641547

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center